Blogging

The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk – Yahoo Finance

Summary

For Immediate Release

Chicago, IL – November 18, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Company LLY, Pfizer Inc. PFE and Novo Nordisk A/S NVO.

Here are highlights from Wednesday’s Analyst Blog:

3 Big Pharma Outperformers to Watch in the Near Term<…….

npressfetimg-2052.png

For Immediate Release

Chicago, IL – November 18, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Company LLY, Pfizer Inc. PFE and Novo Nordisk A/S NVO.

Here are highlights from Wednesday’s Analyst Blog:

3 Big Pharma Outperformers to Watch in the Near Term

The recently ended third-quarter earnings season was a good one for the drug and biotech sector with many companies beating estimates on both counts. Some companies also raised their expectations for both earnings and sales, reflecting their optimistic outlook for the fourth quarter and 2022, in general.

The drug/biotech sector has played a key role in bringing global economic development on track by providing vaccines to fight the dreadful COVID pandemic. While breakthrough infections continue, the vaccines have definitely lowered the risk of severe disease and death rates.

At the same time, though some treatments are already available, more refined medicines (antibodies and oral antiviral pills) are being developed to treat as well as prevent COVID to reduce the spread of the infection. The world keenly watched the developments of this sector last year and continues to do so. People are invested in stocks of big drugmakers for the relative stability they provide.

Here we have highlighted three bigshot drugmakers, Eli LillyPfizer and Novo Nordisk, which have outperformed the industry this year and are good stocks to hold for the next few months and beyond.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Eli Lilly

Lilly’s stock is up 52.7% this year so far compared with a 16.1% increase of the industry.  Earnings estimates for 2021 have gone up from $7.87 to $7.93 per share over the past 60 days

Lilly has some intriguing pipeline assets in its portfolio for cancer, diabetes and Alzheimer’s. It recently submitted regulatory applications for dual GIP and GLP-1 receptor agonist tirzepatide for type II diabetes. Also, it has initiated a rolling submission for another key candidate donanemab for early Alzheimer’s disease. Both candidates have multibillion-dollar sales potential.

Lilly’s revenue growth is being driven by higher demand for drugs like Trulicity, Taltz, and others. Higher revenues from Lilly’s COVID-19 therapies benefited sales in the third quarter as the spread of the Delta variant led to a sharp rise in infection rates in the quarter.

Lilly’s COVID-19 antibody cocktail, bamlanivimab plus etesevimab, was granted emergency approval by the FDA in February 2021 to treat mild-to-moderate COVID-19 in high-risk patients based on data from the BLAZE-1 study. In September, the FDA expanded the EUA for the cocktail …….

Source: https://finance.yahoo.com/news/zacks-analyst-blog-highlights-eli-122812563.html